Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.
Guner R, Hasanoglu I, Kayaaslan B, Aypak A, Akinci E, Bodur H, Eser F, Kaya Kalem A, Kucuksahin O, Ates I, Bastug A, Tezer Tekce Y, Bilgic Z, Gursoy FM, Akca HN, Izdes S, Erdem D, Asfuroglu E, Hezer H, Kilic H, Cıvak M, Aydogan S, Buzgan T.
Guner R, et al. Among authors: akinci e.
J Infect Public Health. 2021 Mar;14(3):365-370. doi: 10.1016/j.jiph.2020.12.017. Epub 2020 Dec 29.
J Infect Public Health. 2021.
PMID: 33647553
Free PMC article.